Published in AIDS Weekly, June 7th, 2004
"Our previous study suggested that the p2gag peptide, AEAMSQVTNTIM, inhibits human immunodeficiency virus type 1 (HIV-1) protease (PR) activity in vitro," wrote researchers in Japan. "In this study, Ala substitutions (Met4Ala and Thr8Ala) and deletion of amino acid Asn9 within the nona p2gag peptide (AEAMSQVTN) were found to decrease the inhibitory effect on HIV-1 PR activity.
"Furthermore, treatment of PMA-activated latently infected T lymphocytes, ACH-2 cells, with the p2gag peptide (100 and 250 PM) resulted in a decrease...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.